AIM:To investigate the clinical effects of intravitreal Bevacizumab for 26 cases with retinopathy of prematurity(ROP)in Zone Ⅰ.

METHODS:A retrospective study. Totally 26 ROP infants between September 2013 and October 2014 diagnosed as high-risk ROP in Zone Ⅰ had been treated with intravitreal bevacizumab. They were divided into three groups, pre-threshold ROP, threshold ROP and acute posterior ROP(APROP). Postoperative effects were compared.

RESULTS:There were 26 infants(52 eyes)diagnosed as ROP in Zone Ⅰ, including 3 infants( 6 eyes)with pre-threshold ROP, 15 infants(30 eyes)with threshold ROP and 8 infants(16 eyes)with APROP. The first operation recovery rate of three groups respectively were 100%(6/6), 60%(18/30)and 75%(12/16), which were not significantly different(P>0.05).

CONCLUSION:Intravitreal bevacizumab for ROP in Zone Ⅰ seems effective and has some advantages over conventional laser treatment, which could be first line treatment for high-risk ROP in Zone Ⅰ.